Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects

Vaccine

Volumn 29, Issue 34, 2011, Pages 5694-5698

  Yanagisawa, Naoki ^a   Maeda, Kazuhiro ^b   Ajisawa, Atsushi ^a   Imamura, Akifumi ^a   Suganuma, Akihiko ^a   Ando, Minoru ^a   Takayama, Naohide ^a   Okuno, Yoshinobu ^b  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b Osaka University   (Japan)

Author keywords

HIV; Immunogenicity; Influenza A (H1N1) 2009 vaccine; Safety

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CD4 LYMPHOCYTE COUNT; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HIV-1; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; VACCINATION;

EID: 79960559059     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.003     Document Type: Article

References (28)

1. Lin J.C., Nichol K.L. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161:441-446.
2. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504.
3. Klein M.B., Lu Y., DelBalso L., Cote S., Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007, 45:234-240.
4. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 6(59):1-62. RR-8.
5. Geretti A.M., Brook G., Cameron C., Chadwick D., Heyderman R.S., MacMahon E., et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008, 9:795-848.
6. Anema A., Mills E., Montaner J., Brownstein J.S., Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med 2008, 9:57-61.
7. Atashili J., Kalilani L., Adimora A.A. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006, 6:138.
8. Bautista E., Chotpitayasunondh T., Gao Z., Harper S.A., Shaw M., Uyeki T.M., et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010, 362:1708-1719.
9. Ormsby C.E., Rosa-Zamboni D.D., Vazquez-Perez J., Ablanedo-Terrazas Y., Vega-Barrientos R., Gomez-Palacio M., et al. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS 2011, 25:435-439.
10. Bickel M., Wieters I., Khaykin P., Nisius G., Haberl A., Stephan C., et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24:F31-F35.
11. Tebas P., Frank I., Lewis M., Quinn J., Zifchak L., Thomas A., et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010, 24:2187-2192.
12. Crum-Cianflone N.F., Eberly L.E., Duplessis C., Maguire J., Ganesan A., Faix D., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011, 52:138-146.
13. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
14. Crum-Cianflone N.F., Iverson E., Defang G., Blair P.J., Eberly L.E., Maguire J., et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 2011, 29:3183-3191.
15. Orlando G., Pariani E., Mazza F., Tanzi E., Meraviglia P., Gianelli E., et al. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS 2010, 24:2142-2143.
16. Bickel M., von Hentig N., Wieters I., Khaykin P., Nisius G., Haberl A., et al. Immune response after two doses of the novel split virion. Adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011, 52:122-127.
17. Soonawala D., Rimmelzwaan G.F., Gelinck L.B., Visser L.G., Kroon F.P. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011, 6(1):e16496.
18. Kajaste-Rudnitski A., Galli L., Nozza S., Tambussi G., Di Pietro A., Pellicciotta G., et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011, 25:177-183.
19. Fabbiani M., Di Giambenedetto S., Sali M., Farina S., Sansonetti P., Tamburrini E., et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 2011, 29:2836-2839.
20. Ho J., Moir S., Wang W., Posada J.G., Gu W., Rehman M.T., et al. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS 2011, 25:295-302.
21. Yamanaka H., Teruya K., Tanaka M., Kikuchi Y., Takahashi T., Kimura S., et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acq Immune Def Synd 2005, 39:167-173.
22. Effros R.B., Fletcher C.V., Gebo K., Halter J.B., Hazzard W.R., Horne F.M., et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008, 47:542-553.
23. Molina-Pinelo S., Vallejo A., Diaz L., Soriano-Sarabia N., Ferrando-Martinez S., Resino S., et al. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation. J Antimicrob Chemother 2009, 64:579-588.
24. Lange C.G., Lederman M.M., Medvik K., Asaad R., Wild M., Kalayjian R., et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003, 17:2015-2023.
25. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
26. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
27. Evison J., Farese S., Seitz M., Uehlinger D.E., Furrer H., Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009, 48:1402-1412.
28. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.